Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Pickard

Urology Flower Mound, TX Medical Doctor

NPI 1003805789 CMS profile 90716

4370 Medical Arts Dr, Suite 105, Flower Mound, TX 75028

Open in the dashboard

General payments

$4,186

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Pickard of Flower Mound, TX is reported in the CMS Open Payments database as having received $4,186 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $852 38
2024 General $706 31
2023 General $811 41
2022 General $717 35
2021 General $210 10
2020 General $260 12
2019 General $630 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Pickard
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to John Pickard were reported at $852. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year John Pickard Urology median Middle half National median
2019 $630 $480 $147–$1,201 $163
2020 $260 $246 $87–$645 $114
2021 $210 $358 $111–$1,000 $132
2022 $717 $476 $143–$1,263 $149
2023 $811 $560 $168–$1,461 $160
2024 $706 $563 $170–$1,464 $164
2025 $852 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $534 26 payments
  2. Astellas Pharma US Inc $511 28 payments
  3. Pfizer Inc. $480 28 payments
  4. Sumitomo Pharma America, Inc. $420 19 payments
  5. Dendreon Pharmaceuticals LLC $221 12 payments
  6. Endo Pharmaceuticals Inc. $210 12 payments
  7. Antares Pharma, Inc. $153 7 payments
  8. Merck Sharp & Dohme Corporation $153 7 payments
  9. AbbVie, Inc. $151 7 payments
  10. Axonics Modulation Technologies, Inc. $100 6 payments
  11. Other $1,253 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,921 204 payments
  2. Education $265 3 payments
Products named General payments · program years 2019–2025
  1. XTANDI $733 44 payments
  2. ERLEADA $547 27 payments
  3. ORGOVYX Oncology $419 24 payments
  4. ORGOVYX Hormone Therapy $386 17 payments
  5. XIAFLEX $300 16 payments
  6. MYRBETRIQ $240 17 payments
  7. PROVENGE $221 12 payments
  8. XYOSTED $133 6 payments
  9. ORGOVYX Prostate Cancer $132 6 payments
  10. KEYTRUDA $131 6 payments
  11. Other $1,696 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,496

Median for Urology: 1,053

Drug cost

$814,892

Median for Urology: $101,464

Branded share of claims

23.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 49 $642,502
Myrbetriq Mirabegron Brand 90 $88,369
Gemtesa Vibegron Brand 44 $35,530
Tamsulosin Hcl Generic 1,087 $18,850
Dutasteride Generic 143 $5,306
Finasteride Generic 235 $3,556
Silodosin Generic 28 $3,210
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 94 $2,437
Oxybutynin Chloride Generic 135 $2,262
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 100 $2,181

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$170,767

Of which drugs: $7,565

Medicare patients

670

Average age 75

Services billed

5,046

100 women, 570 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 37%
Diabetes 27%
Cancer 26%
Chronic kidney disease 24%
Atrial fibrillation 20%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 41 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $153
  • PFIZER INC. $39
$192 — —
XTANDI
  • PFIZER INC. $39
  • Astellas Pharma US Inc $23
$62 49 —
BOTOX
  • AbbVie, Inc. $58
$58 — —
XIAFLEX
  • Endo USA, Inc. $45
$45 — —
ERLEADA
  • Janssen Biotech, Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record